Lucid Diagnostics Inc. — Q3 2021 Form 10-Q
Business context and period. The unaudited filing covers the three and nine months ended September 30, 2021. Lucid, then a majority-owned PAVmed subsidiary, is a commercial-stage diagnostics company developing and commercializing EsoGuard, a laboratory-developed test, and the EsoCheck cell-collection device for detecting esophageal precancer and cancer in patients at risk due to GERD. Results are for Lucid as a stand-alone legal entity.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0.200 million | — | $0.200 million | — |
| Cost of revenue | $0.144 million | — | $0.144 million | — |
| Gross profit (margin) | $0.056 million (27.9%) | — | $0.056 million (27.9%) | — |
| Operating expenses | $6.566 million | $2.022 million | $16.234 million | $5.549 million |
| Operating loss | $(6.510) million | $(2.022) million | $(16.179) million | $(5.549) million |
| Interest expense | $0.447 million | — | $0.594 million | — |
| Net loss | $(6.957) million | $(2.022) million | $(16.772) million | $(5.549) million |
| Basic and diluted loss per share | $(0.49) | $(0.14) | $(1.19) | $(0.39) |
At September 30, 2021, cash was $21,336; current assets were $2.505 million and current liabilities were $27.431 million, a working-capital deficit of approximately $24.927 million. Total assets were $3.296 million, total liabilities $27.431 million, and stockholders’ deficit $24.134 million. Current liabilities included a $22.4 million PAVmed note principal and $1.882 million owed to PAVmed for fees, operating expenses and interest.
For the first nine months, operating cash use was $7.791 million and investing cash use was $0.038 million; financing provided $7.739 million, principally PAVmed working-capital advances. Cash declined by $0.090 million to $21,336. The filing reports no conventional gross-debt total beyond the PAVmed promissory note and related-party balances.
Changes versus prior comparable periods
- Lucid recorded its first reported revenue: $0.2 million in Q3, arising from an August 2021 commercialization agreement with ResearchDx (RDx). Revenue comprised $0.1 million per month in August and September.
- Q3 net loss increased to $6.957 million from $2.022 million. Nine-month net loss increased to $16.772 million from $5.549 million.
- Nine-month operating expenses rose $10.685 million. The principal reported drivers included higher stock-based compensation and professional fees, expanded commercial activity, and increased clinical-trial and product-development costs.
- Stock-based compensation was $6.157 million for the first nine months of 2021 versus $0.049 million a year earlier, including substantial restricted-stock expense. This is a significant noncash expense.
Outlook, commentary, and risks
- Management expects recurring operating losses and continued spending on commercialization, research and development, and clinical trials. It gave no specific revenue or earnings guidance.
- Management stated that cash on hand, including IPO proceeds, was expected to fund operations for one year from the financial-statement issuance date. After quarter-end, Lucid reported a $70.0 million gross IPO, before $4.9 million underwriting fees and approximately $0.7 million offering costs.
- On October 13, 2021, PAVmed converted the $22.4 million note principal into 15,803,200 Lucid shares at the contractual $1.42 conversion price. This removed the principal as debt but increased share count; the filing does not say that accrued interest was converted.
- Commercialization and reimbursement remain uncertain: Lucid was pursuing private-payor coverage and awaiting a Medicare local coverage determination. The company also sought FDA premarket approval through two clinical trials; EsoCheck had FDA 510(k) clearance, while EsoGuard was marketed as an LDT.
- Key risks include limited operating history, market acceptance, regulatory approval, ability to raise capital, clinical-trial execution, intellectual-property protection, reliance on PAVmed and external suppliers/laboratory partners, and possible COVID-19 effects on operations, healthcare access and trials.
- Related-party arrangements are material: PAVmed provided operating personnel and funding, and Lucid recorded $2.510 million of MSA fees for the first nine months. The CWRU license also carries sales-based royalties and a $200,000 payment upon the remaining FDA PMA-submission milestone.
Important facts for investors to verify
- Confirm the post-quarter financing effects, including the note conversion, IPO net proceeds, and resulting dilution. The filing gives differing IPO completion dates in different sections (October 14 and October 18).
- Reconcile share-count disclosures: the filing reports 34,917,907 shares after the IPO in one section and 36,808,647 shares outstanding as of November 18 on the cover.
- Track revenue growth, test volumes, unit economics and gross margin as commercialization scales beyond the initial RDx agreement.
- Check progress on Medicare and private-payor coverage, FDA PMA trials, and manufacturing transfer to Coastline.
- Assess cash burn and runway against management’s one-year funding statement, including ongoing operating losses and related-party costs.
- Note that the cover page marks “No” for having filed all required Exchange Act reports during the preceding 12 months; verify the company’s reporting history and explanation.